The curve would be nice to see, we would hope the original placebo group beat the expected deterioration. However original dosed beating original placebo even more over time is the number 1 finding an OLE can have imo. Especially with the effect size getting so much larger and p size smaller towards 192 weeks. It's harder to poke holes in this type of analysis than with a look at "absolute" numbers where critics would say "you can't make cross comparisons with other trials." However clearly though it would be better if original placebo have deteriorated less than expected. As stated before though by the start of OLE they would have averaged 74-75 years old with MMSEs around 22 so about to enter early moderate AD. Unforuntately likely harder for these patients to be helped as much by an AD drug.
Market Data 
Markets 
AI
